Search

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.

… Wednesday, February 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center. Published in the February

In order to preserve healthcare resources and provide exceptional care, our teams have been working together to develop new and innovative ways to treat our patients during the COVID-19 pandemic. MSK radiation oncologists rapidly re-evaluated our rectal cancer practice policies during this public health emergency.

… Friday, May 15, 2020 Cancer care is essential and should not be put on hold. Here at Memorial Sloan Kettering (MSK) we’ve put in place the strictest safety measures to ensure our patients continue to receive world-class cancer care in the safest environment possible. In order to preserve healthcare resources

Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches have fundamentally shifted the paradigm from providing short-term palliation and pain relief to delivering durable tumor control with fewer morbidities than older approaches. Therefore, cancer patients who have symptoms of spinal cord compression should be referred for surgical evaluation as soon as possible.

… Thursday, June 14, 2018 Spinal cord compression due to spinal metastases is a medical emergency. Modern treatment approaches — minimally invasive surgical techniques and spinal stereotactic radiosurgery (SSRS) — have fundamentally shifted the paradigm from providing short-term palliation and pain relief

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.

… Wednesday, November 15, 2017 Summary The FDA’s authorization of MSK-IMPACT sets a precedent for future authorization of tests developed by both academic and commercial labs. The US Food and Drug Administration has announced the authorization of MSK-IMPACT™ . The test was developed by Memorial Sloan Kettering

Informal fall and winter gatherings promoted and encouraged fellowship among students.

… Monday, March 1, 2010 Fostering a rich, supportive, and diverse community in which to study is high on the school’s agenda. Informal fall and winter gatherings promoted and encouraged fellowship among students. A School Tradition — Celebrate Halloween At Gerstner Sloan Kettering, Halloween is one of

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

… Monday, June 22, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR) , the American Society of Clinical Oncology (ASCO) , and the American Society of Hematology (ASH) organizations: American

Clinically meaningful secondary cancer occurred in non-small cell lung cancer survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at MSK. The findings underscore the importance of risk-adapted, symptom-responsive survivorship care that includes evaluating heritable risk.

… Thursday, January 22, 2026 Clinically meaningful secondary cancer occurred in non-small cell lung cancer (NSCLC) survivors, both within and beyond the thorax and over a prolonged period, according to a new study by a multidisciplinary team of lung cancer experts at Memorial Sloan Kettering Cancer Center

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select patients with advanced solid tumors, NSCLC, and pancreatic cancer. MSK researchers also presented new insights about mismatch repair deficient solid tumors that may inform tailoring personalized treatments.

… Monday, October 20, 2025 Memorial Sloan Kettering Cancer Center (MSK) researchers presented exciting advances in medical oncology for a range of cancer types at the European Society for Medical Oncology Congress 2025 held October 17 to 21 in Berlin, Germany. Highlights included the latest updates on

In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation.

… Thursday, November 13, 2014 Summary In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation. About three billion base pairs make up the human genome. But less than 2 percent of that material contains the sequences for genes that

A drug was shown to improve outcomes in women with HER2-positive early breast cancer when added to standard therapy.

… Monday, June 5, 2017 Summary Women with HER2-positive breast cancer typically receive drugs that block the HER2 protein combined with chemotherapy. A large clinical trial shows that pertuzumab reduces the risk of recurrence in certain women with breast cancer. Update: On December 20, 2017 the FDA approved